Ethicon, part of the Johnson & Johnson Medical Devices Companies launched SURGICEL® Powder, an absorbable haemostat in Australia, New Zealand and Thailand.
During open surgical procedures, disruptive bleeding occurs more than 60 percent of the time. This can have substantial effect on clinical outcome and is associated with high mortality rates. A recent innovation by Ethicon designed to help surgeons to have more efficient control over disruptive bleeding during surgery is a powered adjunctive haemostat known as SURGICEL Powder.
Launched in March 2020 in Australia, New Zealand and Thailand the powder is designed to stop continuous bleeding effectively during surgery. Its easy application across broad surfaces makes it well-suited for use in wide range of surgeries. It is already available in Singapore and Hong Kong, with plans to launch in Japan, Malaysia and India later this year.
Comorbidities such as diabetes, chronic obstructive pulmonary disease, and patients under anticoagulant medications can increase the risk of disruptive bleeding during surgery.
Study conducted in the USA found that out of 1.6 million surgeries showed 30 percent of patients experienced some kind of bleeding-related complication. SURGICEL Powder thus aims to provide a targeted approach to stop bleeding quickly, within 30 seconds. Its versatility and ease in handling also allows for use in a wide range of surgical procedures. This absorbable adjunctive haemostat will be able to minimize cost and product waste as well as give surgeons a less time consuming option.
“In a region like Asia Pacific where the diversity of patients is vast, it’s imperative that we innovate technologies that consistently meet their unique needs,” said Alex Koulaouzos, APAC Franchise Director, Ethicon Biosurgery. “Through SURGICEL Powder, we have been able to combine our expert knowledge in science and technology to provide clinicians and patients with a better surgical experience and clinical outcome.”
On top of its benefits in stopping bleeding, SURGICEL Powder offers bactericidal activity in vitro against all five forms of hospital-acquired pathogens – MRSA, MRSE, VRE, PRSP, and E. Coli. It is also fully absorbable within 7 to 14 days and contains an aggregate of oxidized regenerated cellulose fibre fragments to help control capillary, venous, and small arterial haemorrhages.
SURGICEL Powder is built on proven SURGICEL® Absorbable Haemostat technology and was recently named a “Gold Winner” in the “Drug-Delivery Devices and Combination Products” by the Medical Design Excellence Awards. The SURGICEL Family of Absorbable Haemostats is backed by more than 50 years of proven safety and efficacy. [APBN]